Comparative Pharmacology
Head-to-head clinical analysis: FIASP versus FIASP PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIASP versus FIASP PENFILL.
FIASP vs FIASP PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FIASP is an insulin aspart formulation with faster absorption due to added L-arginine and niacinamide. It activates insulin receptor tyrosine kinase, promoting glucose uptake via GLUT4 translocation.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis and enhances protein synthesis.
Subcutaneous injection at mealtimes, dose individualized. Typical starting total daily dose 0.5-1 unit/kg/day, given as 50% bolus and 50% basal. Bolus dose: 1-2 units or 0.1-0.2 units/kg per meal.
Subcutaneous injection. Individualized based on blood glucose levels. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into multiple doses, with 50-70% as mealtime insulin and remainder as basal. For type 2 diabetes: 4-6 units with largest meal, titrated up by 2 units every 3-4 days based on glucose monitoring.
None Documented
None Documented
0.7-1.0 hours (ultra-rapid acting insulin; terminal half-life from subcutaneous absorption, not intravenous elimination).
0.5–1.0 hours (subcutaneous); terminal half-life corresponds to absorption rate-limited elimination due to rapid dissociation from insulin receptor.
Renal: Approximately 60-80% of insulin aspart is excreted via the kidneys following degradation. Fecal/biliary excretion accounts for <10%.
Primarily renal (glomerular filtration and tubular reabsorption); less than 1% excreted unchanged in bile/feces.
Category C
Category C
Insulin Analogue
Insulin Analogue